Small Cap Cardiological Companies Help Patients Thrive
Ideas get bigger when you share them...
August 20, 2013 (www.investorideas.com newswire) About 600,000 people die each year in America from heart disease, making this medical issue the cause for one in every four deaths in the US. While future technology may make it easier to diagnose and treat heart disease, today’s technological options for cardiological intervention may be able to reduce the risk of complications and increase recovery time for patients facing heart disease.
Small cap companies operating in the cardiological intervention area may not yet have approval for artificial heart technology, but they are making huge strides at introducing innovative technology to the industry. New technology investment in many areas related to symptoms of heart problems may be able to help patients recover. A wide range of small cap companies are working on solutions ranging from products for surgical intervention to therapeutic devices for people with cardiac problems.
One company operating in the cardiological intervention sphere is Atlanta, GA-based CryoLife, Inc (NYSE:CRY). The company recently gained provisional FDA approval for an Investigational Device Exemption for their PerClot product. PerClot is a hemostat designed to be used when control of bleeding by conventional means doesn’t work or is impractical. PerClot has been distributed in overseas markets since the fourth quarter of 2010. CRY closed August 19th at $6.56, down $0.17, with a market cap of $181.45 million. Their 52-week trading range is $5.19 - $7.80.
Novadaq Technologies Inc, based in Mississagua, Ontario (Nasdaq:NVDQ) creates and markets surgical imaging products designed to help surgeons visualize blood vessels during surgery. The company recently announced their acquisition of the “Trapper” brand of surgical imaging technology from Digirad Corporation (Nasdaq:DRAD). Novadaq acquired 5 patents and 13 exclusive licenses for surgical imaging products. NVDQ closed August 19th at $13.44, down $0.23, with a market cap of $650.51 million. Their 52-week trading range is $7.48 - $15.07.
Merit Medical Systems, Inc (Nasdaq:MMSI), based in South Jordan, UT, develops, manufactures and markets devices for both diagnostics and surgical intervention. Merit manufactures many products commonly found in cardiac cath labs, from vascular compression devices to the Merit line of products used during intra aortic balloon procedures. MMSI closed August 19th at $13.03, down $0.09, with a market cap of $558.02 million. Their 52-week trading range is $9.15 - $15.37.
Latham, NY-based AngioDynamics, Inc (Nasdaq:ANGO) recently announced FDA 510(k) clearance for their Xcela Plus Port Family with PASV Technology. The company’s ports show a 73% reduction in occlusion rates when compared to conventional CT ports. AngioDynamics also creates devices for use in image-guided, minimally invasive procedures. ANGO closed August 19th at $10.99, down $0.33, with a market cap of $394.10 million. Their 52-week trading range is $9.52 - $12.91.
While heart disease affects people around the globe, both large- and small-cap companies are working on solutions to treat this problem. From surgical devices designed to help surgeons during cardiac procedures to pumps that help regulate medication, small cap companies in the heart health field are working on new technology investment with the hopes of developing the treatments, interventions, and devices to help cardiac patients thrive.
The About Small Cap blog covers breaking news on small cap stocks from around the world, delving deep into pressing issues both large and small that affect small caps. For example, we recently covered groundbreaking news about artificial heart technology in the small cap world. We write about things like natural gas drilling and interviews with notable personalities across a wide variety of industries, like Elemer Piros in the biotech sector.
This news is published on the Investorideas.com Newswire and its syndicated partner network
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.